C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY

Clinical trials for C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY explained in plain language.

Never miss a new study

Get alerted when new C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY trials appear

Sign up with your email to follow new studies for C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Experimental drug aims to protect kidneys in inflammatory diseases

Disease control Not yet recruiting

This study tests an experimental drug called ADX-097 in people aged 16 and older with three kidney conditions: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The drug is given as an injection under the skin and is designed to reduce inflammation and protein leakage in t…

Matched conditions: C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY

Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control

Last updated Jul 11, 2026 00:00 UTC

C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY

Get alerted when new C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY trials appear

Experimental drug aims to protect kidneys in inflammatory diseases